BRAF is known as an oncogene as mutation in this gene drives tumorigenesis in a lot of cancer types including colorectal cancer, thyroid carcinoma, melanoma, etc. Recently, a researcher investigated the mechanism of the low expression of RIPK3 in most cancer cell lines and found that BRAF along with AXL were two main oncogenes responsible for the loss of RIPK3 repression and resistance of cancer cells to necroptosis [27]. The gene discussed is BRAF; the disease is thyroid gland carcinoma.